Cocrystal Pharma Inc. (COCP) 0.6649 $COCP
Patience Pays Off for Opko and Cocrystal Investors, Will It Also for Pershing Gold?
ACCESSWIRE - Wed Feb 11, 8:26AM CST
NEW YORK, NY / ACCESSWIRE / February 11, 2015 / Teva (NYSE:TEVA) has a new chairman. As of February 5 and after four and a half years at the helm of the largest generics manufacturer in the world, Dr. Phillip Frost has resigned his position. This was announced back in June and is no surprise, and wouldn't be all that noteworthy if not for the fact that other companies that Dr. Frost is heavily involved and invested in are suddenly making rather large upside moves.
GILD: 101.90 (+1.10), OPK: 13.80 (-0.28), TEVA: 56.77 (-0.58)
The Golden Long: Frost's Pershing Gold Poised For A Significant Upside Move
Wall Street Advisors - Seeking Alpha - Wed Feb 11, 3:28AM CST
Gold is off to a strong start in 2015. Gold priced in USD has performed well, up about 6% so far year to date. With the recent strength of the U.S. dollar, though, it is surprising for gold to also look so strong as they typically move at an inverse....
OPK: 13.80 (-0.28), MDW: 0.70 (+0.02)
Dengue Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 7:45PM CST
The report "Dengue - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Dengue. Dengue is a disease caused by bite of the mosquito (Aedes Mosquito) which is infected with a dengue virus. The disease can affect a person through fever, headache, muscle and joint pain. The disease if not cured on time may result into fatal occurrences like dengue hemorrhagic fever. The disease may also result in failure of the circulatory systems of the body. Dengue is found in the Asian Subcontinent. These are primarily the regions wherein the population is crowded & there is scope for the mosquitoes to quantify. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/dengue-pipel...eport.html .
MGNX: 34.09 (+0.10), JNJ: 99.62 (+1.18), UTHR: 151.11 (+3.59), MRK: 58.81 (-0.07), NNVC: 2.97 (-0.05), GSK: 47.94 (+1.99), SIGA: 1.95 (-0.01)
Biotechs to Follow in 2015 off Fresh Insider Moves
ACCESSWIRE - Tue Jan 06, 9:00AM CST
NEW YORK, NY / ACCESSWIRE / January 6, 2015 / Insider moves are always interesting to equity traders no matter where they occur, but more than any other sector, insider buys tend to inspire the most chatter around biotech. This is mostly due to the esoteric science and trial statistics that often determine the fate of a firm, which company and other biotech insiders tend to know more about than even premium hedge fund operators.
ADXS: 7.18 (+0.06), SGEN: 31.57 (+0.36), GILD: 101.90 (+1.10), OPK: 13.80 (-0.28), MRK: 58.81 (-0.07), IBB: 323.46 (+3.04), AGIO: 118.55 (+0.11), TEVA: 56.77 (-0.58), CELG: 115.88 (+0.16)
Cocrystal Pharma: Small Cap Company With Transformative Merger
Leonard Yaffe - at Seeking Alpha - Thu Nov 27, 12:51PM CST
Cocrystal and RFS complete marriage
Seeking Alpha - at Seeking Alpha - Tue Nov 25, 11:59AM CST
Cocrystal Pharma and RFS Pharma Merge to Create Advanced Antiviral Development Organization
Marketwired - Tue Nov 25, 8:52AM CST
Cocrystal Pharma, Inc. (OTCQB: COCP), a biotechnology company developing novel antiviral therapeutics for human diseases, today announced the closing of its merger with RFS Pharma, LLC, a privately owned biotech company founded by renowned drug developer, Dr. Raymond Schinazi. Since 2004, RFS Pharma has been working on the development of innovative drugs to treat human viral diseases.
OPK: 13.80 (-0.28)
Cocrystal Pharma Reports Third Quarter Financial Results and Select Program Updates
Marketwired - Fri Nov 14, 8:15AM CST
Cocrystal Pharma, Inc. (the "Company"
(OTCQB: COCP), a biotechnology company focused on developing new antiviral therapeutics for human diseases, today reported financial results for the third quarter ended September 30, 2014.
Cocrystal Pharma Develops Novel Ebola Screening Technology
Marketwired - Thu Oct 23, 8:26AM CDT
Cocrystal Pharma, Inc. (OTCBB: COCP), a biotechnology company developing new antiviral therapeutics for human diseases, today reported that it has developed what it believes to be the first high-throughput screening technology for inhibitors of a key essential Ebola virus gene product.
OPK: 13.80 (-0.28)
Cocrystal Pharma records higher Q2 operating expenses of USD1.4m
M2 - Mon Aug 18, 7:46AM CDT
Biotechnology company Cocrystal Pharma (OTC BB:COCP) stated on Friday that its operating expenses were USD1.4m for the second quarter ended 30 June 2014.
Cocrystal Pharma Reports Second Quarter Financial Results
Marketwire - Fri Aug 15, 6:30AM CDT
Cocrystal Pharma, Inc. (the "Company" (OTCBB: COCP) (OTCQB: COCP), a biotechnology company developing new antiviral therapeutics for human diseases, today reported financial results for the second quarter ended June 30, 2014.
Cocrystal Pharma, Inc. - "World Hepatitis Day and a Continued Global Unmet Medical Need"
ACCESSWIRE - Mon Jul 28, 8:47AM CDT
New York, NY / July 28, 2014 / Cocrystal Pharma, Inc. (OTCBB: COCP) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO, Dr. Gary Wilcox. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
OTC Stocks Trading News: Cocrystal Pharma, Inc. Minerco Resources, Inc. MediJane Holdings, Inc. Applied DNA Sciences, Inc. mCig Inc
PR Newswire Europe - Tue Jul 22, 7:02AM CDT
LONDON, July 22, 2014 /PRNewswire/ --
APDN: 3.45 (+0.05)
H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/748t6b/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for H5N1 Infection (Avian Influenza) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the H5N1 Infection (Avian Influenza) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the H5N1 Infection (Avian Influenza) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Johnson & Johnson - Autoimmune Technologies, LLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Generex Biotechnology Corporation - Takeda Pharmaceutical Company Limited - Nanotherapeutics, Inc. - Novartis AG - CEL-SCI Corporation - OPKO Health, Inc. - Hemispherx Biopharma, Inc. - Medicago Inc. - BioDiem Ltd - NanoViricides, Inc. - Medigen Biotechnology Corporation - SIGA Technologies, Inc. - XOMA Corporation - Green Cross Corporation - Antigen Express, Inc. - Adimmune Corporation - TechnoVax, Inc. - Cocrystal Pharma, Inc. - PaxVax - Vivaldi Biosciences Inc. - Aprogen, Inc. - Akshaya Bio Inc. - Gemmus Pharma Inc. For more information visit http://www.researchandmarkets.com/research/74..._infection
CVM: 0.84 (-0.01), EBS: 28.76 (-0.12), GSK: 47.94 (+1.99), NNVC: 2.97 (-0.05), SIGA: 1.95 (-0.01), JNJ: 99.62 (+1.18), OPK: 13.80 (-0.28), XOMA: 3.41 (-0.01), NVS: 102.20 (-0.17)
Rhinovirus Infection - Pipeline Review, H1 2014
M2 - Fri Jun 27, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rd8bmd/rhinovirus) has announced the addition of the "Rhinovirus Infection - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Rhinovirus Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rhinovirus Infection and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Rhinovirus Infection - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Rhinovirus Infection pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Boehringer Ingelheim GmbH - Theraclone Sciences, Inc. - Alios BioPharma, Inc. - Cocrystal Pharma, Inc. - Sealife PHARMA GMBH - Biota Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/rd8bmd/rhinovirus
BOTA: 2.60 (-0.06)
Patience Pays Off for Opko and Cocrystal Investors, Will It Also for Pershing Gold?
ACCESSWIRE - Wed Feb 11, 8:26AM CST
NEW YORK, NY / ACCESSWIRE / February 11, 2015 / Teva (NYSE:TEVA) has a new chairman. As of February 5 and after four and a half years at the helm of the largest generics manufacturer in the world, Dr. Phillip Frost has resigned his position. This was announced back in June and is no surprise, and wouldn't be all that noteworthy if not for the fact that other companies that Dr. Frost is heavily involved and invested in are suddenly making rather large upside moves.
GILD: 101.90 (+1.10), OPK: 13.80 (-0.28), TEVA: 56.77 (-0.58)
The Golden Long: Frost's Pershing Gold Poised For A Significant Upside Move
Wall Street Advisors - Seeking Alpha - Wed Feb 11, 3:28AM CST
Gold is off to a strong start in 2015. Gold priced in USD has performed well, up about 6% so far year to date. With the recent strength of the U.S. dollar, though, it is surprising for gold to also look so strong as they typically move at an inverse....
OPK: 13.80 (-0.28), MDW: 0.70 (+0.02)
Dengue Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 7:45PM CST
The report "Dengue - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Dengue. Dengue is a disease caused by bite of the mosquito (Aedes Mosquito) which is infected with a dengue virus. The disease can affect a person through fever, headache, muscle and joint pain. The disease if not cured on time may result into fatal occurrences like dengue hemorrhagic fever. The disease may also result in failure of the circulatory systems of the body. Dengue is found in the Asian Subcontinent. These are primarily the regions wherein the population is crowded & there is scope for the mosquitoes to quantify. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/dengue-pipel...eport.html .
MGNX: 34.09 (+0.10), JNJ: 99.62 (+1.18), UTHR: 151.11 (+3.59), MRK: 58.81 (-0.07), NNVC: 2.97 (-0.05), GSK: 47.94 (+1.99), SIGA: 1.95 (-0.01)
Biotechs to Follow in 2015 off Fresh Insider Moves
ACCESSWIRE - Tue Jan 06, 9:00AM CST
NEW YORK, NY / ACCESSWIRE / January 6, 2015 / Insider moves are always interesting to equity traders no matter where they occur, but more than any other sector, insider buys tend to inspire the most chatter around biotech. This is mostly due to the esoteric science and trial statistics that often determine the fate of a firm, which company and other biotech insiders tend to know more about than even premium hedge fund operators.
ADXS: 7.18 (+0.06), SGEN: 31.57 (+0.36), GILD: 101.90 (+1.10), OPK: 13.80 (-0.28), MRK: 58.81 (-0.07), IBB: 323.46 (+3.04), AGIO: 118.55 (+0.11), TEVA: 56.77 (-0.58), CELG: 115.88 (+0.16)
Cocrystal Pharma: Small Cap Company With Transformative Merger
Leonard Yaffe - at Seeking Alpha - Thu Nov 27, 12:51PM CST
Cocrystal and RFS complete marriage
Seeking Alpha - at Seeking Alpha - Tue Nov 25, 11:59AM CST
Cocrystal Pharma and RFS Pharma Merge to Create Advanced Antiviral Development Organization
Marketwired - Tue Nov 25, 8:52AM CST
Cocrystal Pharma, Inc. (OTCQB: COCP), a biotechnology company developing novel antiviral therapeutics for human diseases, today announced the closing of its merger with RFS Pharma, LLC, a privately owned biotech company founded by renowned drug developer, Dr. Raymond Schinazi. Since 2004, RFS Pharma has been working on the development of innovative drugs to treat human viral diseases.
OPK: 13.80 (-0.28)
Cocrystal Pharma Reports Third Quarter Financial Results and Select Program Updates
Marketwired - Fri Nov 14, 8:15AM CST
Cocrystal Pharma, Inc. (the "Company"
(OTCQB: COCP), a biotechnology company focused on developing new antiviral therapeutics for human diseases, today reported financial results for the third quarter ended September 30, 2014. Cocrystal Pharma Develops Novel Ebola Screening Technology
Marketwired - Thu Oct 23, 8:26AM CDT
Cocrystal Pharma, Inc. (OTCBB: COCP), a biotechnology company developing new antiviral therapeutics for human diseases, today reported that it has developed what it believes to be the first high-throughput screening technology for inhibitors of a key essential Ebola virus gene product.
OPK: 13.80 (-0.28)
Cocrystal Pharma records higher Q2 operating expenses of USD1.4m
M2 - Mon Aug 18, 7:46AM CDT
Biotechnology company Cocrystal Pharma (OTC BB:COCP) stated on Friday that its operating expenses were USD1.4m for the second quarter ended 30 June 2014.
Cocrystal Pharma Reports Second Quarter Financial Results
Marketwire - Fri Aug 15, 6:30AM CDT
Cocrystal Pharma, Inc. (the "Company"
(OTCBB: COCP) (OTCQB: COCP), a biotechnology company developing new antiviral therapeutics for human diseases, today reported financial results for the second quarter ended June 30, 2014. Cocrystal Pharma, Inc. - "World Hepatitis Day and a Continued Global Unmet Medical Need"
ACCESSWIRE - Mon Jul 28, 8:47AM CDT
New York, NY / July 28, 2014 / Cocrystal Pharma, Inc. (OTCBB: COCP) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO, Dr. Gary Wilcox. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
OTC Stocks Trading News: Cocrystal Pharma, Inc. Minerco Resources, Inc. MediJane Holdings, Inc. Applied DNA Sciences, Inc. mCig Inc
PR Newswire Europe - Tue Jul 22, 7:02AM CDT
LONDON, July 22, 2014 /PRNewswire/ --
APDN: 3.45 (+0.05)
H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/748t6b/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for H5N1 Infection (Avian Influenza) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the H5N1 Infection (Avian Influenza) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the H5N1 Infection (Avian Influenza) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Johnson & Johnson - Autoimmune Technologies, LLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Generex Biotechnology Corporation - Takeda Pharmaceutical Company Limited - Nanotherapeutics, Inc. - Novartis AG - CEL-SCI Corporation - OPKO Health, Inc. - Hemispherx Biopharma, Inc. - Medicago Inc. - BioDiem Ltd - NanoViricides, Inc. - Medigen Biotechnology Corporation - SIGA Technologies, Inc. - XOMA Corporation - Green Cross Corporation - Antigen Express, Inc. - Adimmune Corporation - TechnoVax, Inc. - Cocrystal Pharma, Inc. - PaxVax - Vivaldi Biosciences Inc. - Aprogen, Inc. - Akshaya Bio Inc. - Gemmus Pharma Inc. For more information visit http://www.researchandmarkets.com/research/74..._infection
CVM: 0.84 (-0.01), EBS: 28.76 (-0.12), GSK: 47.94 (+1.99), NNVC: 2.97 (-0.05), SIGA: 1.95 (-0.01), JNJ: 99.62 (+1.18), OPK: 13.80 (-0.28), XOMA: 3.41 (-0.01), NVS: 102.20 (-0.17)
Rhinovirus Infection - Pipeline Review, H1 2014
M2 - Fri Jun 27, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rd8bmd/rhinovirus) has announced the addition of the "Rhinovirus Infection - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Rhinovirus Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rhinovirus Infection and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Rhinovirus Infection - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Rhinovirus Infection pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Boehringer Ingelheim GmbH - Theraclone Sciences, Inc. - Alios BioPharma, Inc. - Cocrystal Pharma, Inc. - Sealife PHARMA GMBH - Biota Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/rd8bmd/rhinovirus
BOTA: 2.60 (-0.06)
